A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
98actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-16 | actual | When the study began enrolling |
| Primary completion | 2025-12-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-08 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cardiovascular
Interventions
- Drug: AZD1705
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs) and serious adverse events (SAEs)
measured Part A: From Screening (Day -60 to Day -2) until Day 113. Part B: From Screening until Day 141
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed